Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry

NCT06417502 · tracked via the Priya Life Science China tracker

Sponsor

Peking Union Medical College Hospital

Phase

Observational

Started

2022-04-29

Last updated

2024-05-16

Condition(s) studied

Autoimmune DiseasesAutoinflammatory Diseases

Study summary

An observational, multi-center, longitudinal registry study for Chinese pediatric patients with rheumatic and immunologic diseases.

Eligibility

Sex

ALL

Min age

—

Max age

18 Years

Healthy volunteers

Inclusion Criteria: * Age \<= 18 years old * Diagnosed with rheumatic and immunologic diseases (including diffuse connective tissue diseases, arthritis, vasculitis, inborn errors of immunity) * Diagnosed and Treated in China Exclusion Criteria: * Disagreement of involving in this study by the patient or his/her family.

Primary outcome measure(s)

Number of Enrolled Patients — up to 10 years
Total number of patients with pediatric rheumatic and immunologic diseases enrolled in the registry

Trial sites (9)

Facility	City	Region	Status
Peking Union Medical College Hospital	Beijing	Beijing Municipality	Recruiting
Beijing Children's Hospital, Capital Medical University	Beijing	Beijing Municipality	Recruiting
Third Hospital of Peking University	Beijing	Beijing Municipality	Recruiting
Chidren's Hospital of Chongqing Medical University	Chongqing	Chongqing Municipality	Recruiting
Shenzhen Children's Hospital	Shenzhen	Guangdong	Recruiting
The University of Hong Kong Shenzhen Institute of Research and Innovation (HKU-SIRI)	Shenzhen	Guangdong	Recruiting
The Second Xiangya Hospital of Central South University	Changsha	Hunan	Recruiting
Children's Hospital of Nanjing Medical University	Nanjing	Jiangsu	Recruiting
Children's Hospital of Zhejiang University School of Medicine	Hangzhou	Zhejiang	Recruiting

More Peking Union Medical College Hospital trials in China

A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors Recruiting

Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT Recruiting

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) Recruiting

An Observational Cohort Study to Obese Patients With Weight Cycling Active, not recruiting

A Comparative Analysis of Mid- to Long-Term Outcomes: Paclitaxel-Coated Balloon With Debulking Versus Paclitaxel-Coated Balloon Alone in the Treatment of Chronic Femoropopliteal Artery Occlusions Starting soon

Other trials for the same condition

JY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases Starting soon

Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases Recruiting

JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases Starting soon

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases Recruiting

Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06417502 on ClinicalTrials.gov ↗ ← All trials in China